FDA approves muscular dystrophy drug built on Children’s National research
October 27, 2023 09:27 ET
|
Children's National Hospital
WASHINGTON, D.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Boys with Duchenne muscular dystrophy (DMD) have a clinically proven, new treatment option with the Food and Drug Administration’s approval...
TOP RANKED ROSEN LAW FIRM Encourages Integra LifeSciences Holdings Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – IART
October 18, 2023 17:16 ET
|
The Rosen Law Firm PA
NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integra LifeSciences Holdings Corporation (NASDAQ: IART)...
ROSEN, TRUSTED INVESTOR COUNSEL, FIRM Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RAIN
August 19, 2023 17:52 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20, 2021 and...
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RAIN
July 27, 2023 11:27 ET
|
The Rosen Law Firm PA
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Rain...
Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma
July 17, 2023 09:00 ET
|
Elevar Therapeutics
FORT LEE, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., and a fully integrated biopharmaceutical company dedicated to elevating...
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
February 14, 2023 20:40 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
Endogena Therapeutics Receives US FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa
February 06, 2023 07:00 ET
|
Endogena
SAN FRANCISCO, TORONTO and ZÜRICH, Switzerland, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Endogena Therapeutics Inc., a clinical-stage biotech company focused on the development of endogenous...
FDA’s Peter Marks, M.D., Ph.D. to deliver Keynote Address at 2023 Muscular Dystrophy Association Clinical & Scientific Conference
January 10, 2023 06:00 ET
|
Muscular Dystrophy Association
New York, NY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Peter Marks, M.D., Ph.D. as the Keynote Speaker at the MDA 2023 Clinical & Scientific...
SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical’s Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI)
December 29, 2022 08:30 ET
|
SeaStar Medical Holding Corporation
Approximately 4,000 children in the U.S. with AKI require Continuous Kidney Replacement Therapy (CKRT) DENVER and MINNEAPOLIS , Dec. 29, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding...
Fragrance Creators Association Amplifies Ongoing Collaboration and Shared Commitment With the FDA to Advance State-of-the-Art Science
October 17, 2022 13:30 ET
|
Fragrance Creators Association
WASHINGTON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The Director of the Food and Drug Administration's (FDA) Office of Cosmetics and Colors Linda Katz, MD, MPH, told members of the Fragrance Creators...